NASDAQ:AEZS Aeterna Zentaris - AEZS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.71 -0.04 (-1.45%) (As of 03/17/2023 06:55 PM ET) Add Compare Share Share Today's Range$2.70▼$2.7450-Day Range$2.61▼$3.8952-Week Range$2.54▼$9.75Volume4,500 shsAverage Volume13,210 shsMarket Capitalization$13.17 millionP/E RatioN/ADividend YieldN/APrice Target$37.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aeterna Zentaris MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,283.8% Upside$37.50 Price TargetShort InterestBearish1.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.04) to ($3.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.80 out of 5 starsMedical Sector790th out of 983 stocksPharmaceutical Preparations Industry377th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingAeterna Zentaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.50, Aeterna Zentaris has a forecasted upside of 1,283.8% from its current price of $2.71.Amount of Analyst CoverageAeterna Zentaris has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.80% of the float of Aeterna Zentaris has been sold short.Short Interest Ratio / Days to CoverAeterna Zentaris has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Aeterna Zentaris has recently increased by 7.01%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAeterna Zentaris does not currently pay a dividend.Dividend GrowthAeterna Zentaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEZS. Previous Next 2.5 News and Social Media Coverage News SentimentAeterna Zentaris has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aeterna Zentaris this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Aeterna Zentaris is held by insiders.Percentage Held by InstitutionsOnly 0.60% of the stock of Aeterna Zentaris is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aeterna Zentaris are expected to decrease in the coming year, from ($3.04) to ($3.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeterna Zentaris is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeterna Zentaris is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeterna Zentaris has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aeterna Zentaris (NASDAQ:AEZS) StockÆterna Zentaris, Inc. operates as a specialty biopharmaceutical company, which engages in the development of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.Read More Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address AEZS Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comShort Interest in Aeterna Zentaris Inc. (NASDAQ:AEZS) Increases By 7.0%March 16, 2023 | finance.yahoo.comPharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)March 20, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 12, 2023 | americanbankingnews.comAeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.comJanuary 17, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Provides Business Update and Outlines Key Upcoming MilestonesJanuary 17, 2023 | benzinga.comAeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19January 17, 2023 | finance.yahoo.comAeterna Zentaris Provides Business Update and Outlines Key Upcoming MilestonesJanuary 10, 2023 | finance.yahoo.comAeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch EventMarch 20, 2023 | Weiss Ratings (Ad)Banking NightmareDuring and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …November 3, 2022 | finance.yahoo.comAeterna Zentaris (AEZS) Reports Q3 Loss, Tops Revenue EstimatesNovember 3, 2022 | finance.yahoo.comAeterna Zentaris Reports Third Quarter 2022 Financial ResultsOctober 14, 2022 | seekingalpha.comAEZS Aeterna Zentaris Inc.August 29, 2022 | finance.yahoo.comAeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo NordiskJuly 19, 2022 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Announces Effective Date of Share ConsolidationJune 9, 2022 | finance.yahoo.comAeterna Zentaris to Present at the JMP Securities Life Sciences ConferenceMay 25, 2022 | seekingalpha.comAeterna Zentaris licensing partner Consilient launches growth hormone deficiency test in EuropeMay 11, 2022 | investing.comAeterna Zentaris Reports Q1 Net Loss of $2.6M, Provides Business OutlookMay 11, 2022 | finance.yahoo.comAeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business OutlookApril 19, 2022 | seekingalpha.comAeterna Zentaris gets European patent related to macimorelin to detect growth hormone deficiencyApril 19, 2022 | finance.yahoo.comAeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in AdultsApril 11, 2022 | finance.yahoo.comAeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on AutoimmunityMarch 29, 2022 | finance.yahoo.comAeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business OutlookMarch 23, 2022 | morningstar.comAeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency | MorningstarMarch 21, 2022 | finance.yahoo.comAeterna Zentaris Says Enrollment In Growth Hormone Deficiency Trial To Continue Into 2023March 17, 2022 | finance.yahoo.comSynlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue EstimatesMarch 10, 2022 | seekingalpha.comAeterna Zentaris expands research program for COVID-19/Chlamydia vaccinesMarch 10, 2022 | finance.yahoo.comAeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine ProgramsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address AEZS Company Calendar Last Earnings11/04/2021Today3/20/2023Next Earnings (Estimated)3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AEZS CUSIPN/A CIK1113423 Webwww.zentaris.com Phone(418) 652-8525Fax418-948-9191Employees11Year FoundedN/APrice Target and Rating Average Stock Price Forecast$37.50 High Stock Price Forecast$37.50 Low Stock Price Forecast$37.50 Forecasted Upside/Downside+1,283.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,370,000.00 Net MarginsN/A Pretax Margin-319.87% Return on Equity-25.10% Return on Assets-17.86% Debt Debt-to-Equity RatioN/A Current Ratio9.82 Quick Ratio9.78 Sales & Book Value Annual Sales$5.26 million Price / Sales2.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.91 per share Price / Book0.25Miscellaneous Outstanding Shares4,860,000Free Float4,851,000Market Cap$13.17 million OptionableOptionable Beta1.43 Social Links Key ExecutivesKlaus Wolfgang PauliniPresident, Chief Executive Officer & DirectorGiuliano La FrattaChief Financial Officer & Senior Vice PresidentMichael TeifelChief Scientific Officer & Senior Vice PresidentNicola AmmerChief Medical Officer & Senior Vice PresidentMatthias GerlachVice President-Manufacturing & Supply ChainKey CompetitorsKazia TherapeuticsNASDAQ:KZIATempest TherapeuticsNASDAQ:TPSTIndaptus TherapeuticsNASDAQ:INDPIterum TherapeuticsNASDAQ:ITRMPasithea TherapeuticsNASDAQ:KTTAView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPSold 700 shares on 2/14/2023Ownership: 0.000%Group One Trading L.P.Sold 4,000 shares on 2/9/2023Ownership: 0.000%Cutler Group LLC CASold 800 shares on 2/7/2023Ownership: 0.000%View All Institutional Transactions AEZS Stock - Frequently Asked Questions Should I buy or sell Aeterna Zentaris stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEZS shares. View AEZS analyst ratings or view top-rated stocks. What is Aeterna Zentaris' stock price forecast for 2023? 1 equities research analysts have issued 1-year target prices for Aeterna Zentaris' shares. Their AEZS share price forecasts range from $37.50 to $37.50. On average, they predict the company's share price to reach $37.50 in the next twelve months. This suggests a possible upside of 1,283.8% from the stock's current price. View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts. How have AEZS shares performed in 2023? Aeterna Zentaris' stock was trading at $3.18 at the beginning of the year. Since then, AEZS stock has decreased by 14.8% and is now trading at $2.71. View the best growth stocks for 2023 here. Are investors shorting Aeterna Zentaris? Aeterna Zentaris saw a increase in short interest in February. As of February 28th, there was short interest totaling 87,000 shares, an increase of 7.0% from the February 13th total of 81,300 shares. Based on an average daily trading volume, of 15,700 shares, the short-interest ratio is presently 5.5 days. Approximately 1.8% of the shares of the stock are short sold. View Aeterna Zentaris' Short Interest. When is Aeterna Zentaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023. View our AEZS earnings forecast. How were Aeterna Zentaris' earnings last quarter? Aeterna Zentaris Inc. (NASDAQ:AEZS) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.25. The biopharmaceutical company earned $0.60 million during the quarter, compared to the consensus estimate of $0.60 million. When did Aeterna Zentaris' stock split? Aeterna Zentaris's stock reverse split on the morning of Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG). What is Aeterna Zentaris' stock symbol? Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS." Who are Aeterna Zentaris' major shareholders? Aeterna Zentaris' stock is owned by a number of retail and institutional investors. Top institutional investors include Group One Trading L.P. (0.00%), Susquehanna International Group LLP (0.00%), Cutler Group LLC CA (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Aeterna Zentaris? Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aeterna Zentaris' stock price today? One share of AEZS stock can currently be purchased for approximately $2.71. How much money does Aeterna Zentaris make? Aeterna Zentaris (NASDAQ:AEZS) has a market capitalization of $13.17 million and generates $5.26 million in revenue each year. The biopharmaceutical company earns $-8,370,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis. How can I contact Aeterna Zentaris? Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The official website for the company is www.zentaris.com. The biopharmaceutical company can be reached via phone at (418) 652-8525, via email at ir@aezsinc.com, or via fax at 418-948-9191. This page (NASDAQ:AEZS) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.